VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
NBYNovaBay Pharmaceuticals, Inc.
$1.47$9M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksNBYCash Flow

NovaBay Pharmaceuticals, Inc. (NBY) Cash Flow Statement

20Y historyFree accessUpdated daily

Liquidity remains a critical concern, as evidenced by a $1.8 million negative free cash flow in 2025Q3 and a questionable $4.8 million dividend payment despite the company's limited cash reserves.

NBY Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05
Cash from Operations-6.97M-5.18M-4.26M-6.65M-9.19M-4.72M-7.93M-5.57M-6.27M-12.13M-18.56M-15.05M-12.97M-6.53M-3.14M2.03M-1.65M-9.94M-6.27M4.74M-3.23M
Operating CF Margin %--52.99%-40.76%-46.2%-90.08%-47.52%-120.15%-44.52%-34.39%-102%-423.62%-1428.37%-372.99%-93.97%-28.51%20.79%-10.51%-147.9%-106.05%309.46%-
Operating CF Growth %-151.9%-21.64%35.96%27.61%-94.7%40.46%-42.4%11.2%48.33%34.61%-23.27%-16.08%-98.67%-107.77%-254.93%223.06%83.42%-58.54%-232.19%246.87%-
Net Income3.24M-7.21M-6.14M-10.61M-5.82M-11.04M-9.66M-6.54M-7.4M-13.15M-18.97M-15.19M-16.04M-7.03M-5.08M-4.31M2.7M-8.11M-5.4M-5.29M-3.46M
Depreciation & Amortization261K381K356K483K119K51K65K266K95K114K164K232K314K341K425K427K373K304K183K74K48K
Stock-Based Compensation4K00220K1.15M701K621K594K2.04M1.75M1.38M1.04M1.02M1.54M1.22M1.4M1.28M983K428K00
Deferred Taxes000000-849K00000-442K037K034K-35K-428K00
Other Non-Cash Items125K2.24M1.96M2.72M-4.6M5.36M688K-1.23M605K2.31M-2.15M-1.68M1.18M-1.13M732K3.26M8K-23K392K356K83K
Working Capital Changes548K-595K-433K533K-38K210K1.2M1.35M-1.6M-3.16M1.02M543K999K-252K-472K1.25M-6.04M-3.06M-1.45M9.6M102K
Change in Receivables-53K291K846K-305K452K-317K2.32M774K-1.51M-1.58M-299K555K159K-940K497K3.25M-3.8M0000
Change in Inventory-355K-272K162K-217K-243K-116K-212K198K369K472K-751K-451K-208K-23K-13.03M1.57M-2.2M0000
Change in Payables1.26M-195K-1.13M667K-163K321K-862K516K-260K-2.16M1.66M-252K1.41M665K345K-319K-70K289K397K00
Cash from Investing01.06M-19K-112K-12.04M-26K-19K-44K-244K-160K-86K2.6M1.41M1.36M-4.67M-1.19M-1.07M10.86M-5.66M-5.51M-1.14M
Capital Expenditures0-6K-19K-112K-52K-26K-19K-44K-244K-160K-123K-68K-141K-148K-119K-203K-731K-610K-663K-362K-123K
CapEx % of Revenue0%0.06%0.18%0.78%0.51%0.26%0.29%0.35%1.34%1.34%2.81%6.45%4.06%2.13%1.08%2.08%4.66%9.07%11.21%23.61%-
Acquisitions01.07M00-11.99M0000037K021K025K00-35K000
Investments---------------------
Other Investing000000000037K128K-21K6K-25K02K35K1K1K1K
Cash from Financing-2.82M1.5M1.91M4.63M16.79M9.76M11.7M5.6M201K19.42M15.6M7.39M9.33M9.47M4.7M-292K1.61M236K17.97M3.46M2.53M
Debt Issued (Net)-7K-1.49M1.53M-105K105K-2.56M2.35M00-1.66M1.66M00-71K-35K-371K-408K83K-31K0-20K
Equity Issued (Net)-1.17M1000K565K1000K1000K1000K1000K1000K01000K1000K227K1000K1000K081K1000K01000K1000K1000K
Dividends Paid-4.82M00000000000000000000
Share Repurchases-1.99M0000000-48K000000000000
Other Financing3.38M-115K-181K1.7M07.11M58K12K201K7.43M2.43M7.16M3.25M6.74M4.74M-2K74K153K716K-93K873K
Net Change in Cash1.58M-2.49M-2.44M-2.13M-4.45M5.01M3.75M-15K-6.31M7.13M-3.04M-5.07M-2.23M4.31M-3.11M542K-1.11M1.16M6.04M2.69M-1.84M
Free Cash Flow-6.97M-5.19M-4.28M-6.77M-9.24M-4.75M-7.95M-5.61M-6.51M-12.29M-18.68M-15.12M-13.11M-6.68M-3.26M1.82M-2.38M-10.55M-6.93M4.38M-3.35M
FCF Margin %-246.36%-53.05%-40.94%-46.97%-90.59%-47.79%-120.44%-44.87%-35.73%-103.35%-426.43%-1434.82%-377.05%-96.1%-29.59%18.71%-15.17%-156.98%-117.27%285.84%-
FCF Growth %-16.39%-21.24%36.74%26.81%-94.73%40.27%-41.63%13.85%47.02%34.19%-23.53%-15.35%-96.38%-104.72%-278.68%176.71%77.45%-52.18%-258.24%230.69%-
FCF per Share-1.19-1.53-35.67-147.09-259.45-165.79-449.90-403.02-520.75-979.76-683.97-553.67-479.97-198.37-110.7268.46-90.06-433.24-676.09670.95-604.69
FCF Conversion (FCF/Net Income)-2.15x0.72x0.44x0.63x1.58x0.43x0.82x0.85x0.85x0.92x0.98x0.99x0.81x0.93x0.62x-0.47x-0.61x1.23x1.16x-0.90x0.93x
Interest Paid00017K049K148K000003K18K18K32K00000
Taxes Paid00024K21K14K14K14K00002K2K23K52K00000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Existential liquidity crisis

Earnings Disconnect Signals Cash Strain

As reported in recent financial statements, NovaBay's operating cash flow consistently trails net income, with an OCF/NI ratio reaching 1.39 in 2025Q3, suggesting that the company's reported earnings are not supported by actual cash generation and that accruals are masking a deeper underlying cash burn.

The persistent gap between net income and operating cash flow indicates that the company is struggling to convert its revenue into liquid assets. This divergence suggests that investors should monitor whether the company is relying on non-cash accounting adjustments to mitigate the appearance of its ongoing operational losses.

Persistent Negative Free Cash Flow

Based on the company's quarterly filings, free cash flow has remained consistently negative, with a 2025Q3 outflow of $1.8 million, highlighting a structural inability to fund operations through internal cash generation and a reliance on external financing to maintain the current business model.

The trajectory of free cash flow indicates that the company is consuming its limited capital reserves at an unsustainable rate. This trend suggests that without a significant pivot in operational efficiency, the company may continue to face severe liquidity pressures that threaten its long-term viability.

Volatile Working Capital Management Trends

According to historical data, working capital changes have been highly erratic, swinging from a $1.3 million inflow in 2025Q1 to a $1.1 million outflow in 2025Q2, which suggests that the company lacks a stable process for managing its receivables and payables effectively.

This volatility in working capital management may indicate difficulties in timing collections from retail partners or managing inventory levels relative to demand. Such instability complicates cash flow forecasting and suggests that the company's liquidity position is highly sensitive to short-term operational fluctuations.

Capital Allocation Amidst Liquidity Crisis

As indicated by recent disclosures, the company utilized $4.8 million for dividends in 2025Q3 despite a negative cash flow position, a decision that appears highly questionable given the company's precarious $430,000 cash balance and the urgent need for capital to sustain core operations.

The allocation of capital toward dividends while the company is actively burning cash warrants further investigation into management's strategic priorities. This approach appears to exacerbate the company's liquidity crisis and may signal a disconnect between capital distribution policies and the firm's actual financial health.

NBY — Frequently Asked Questions

Quick answers to the most common questions about buying NBY stock.

How much cash does NovaBay Pharmaceuticals, Inc. (NBY) generate from operations?

NovaBay Pharmaceuticals, Inc. (NBY) generated $-5.2M in net cash from operating activities in 2024. This reflects the cash generated directly from core business operations.

What is NovaBay Pharmaceuticals, Inc.'s free cash flow?

NovaBay Pharmaceuticals, Inc. (NBY) reported negative free cash flow of $5.2M in 2024, indicating capital requirements exceeded cash from operations.

What is NovaBay Pharmaceuticals, Inc.'s capital expenditure (CapEx)?

NovaBay Pharmaceuticals, Inc. (NBY) spent $0.0M on capital expenditures in 2024. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.